

Maximising the Synergy of Tumour Tissue and Liquid Biopsy Testing in Oncology Clinical Practice

Friday 13 September 2024, 10:15–11:45 CEST

Valencia Auditorium, Hall 5, Fira Barcelona Gran Via, Barcelona, Spain

Chaired by:



Dr. Christian Rolfo
New York, USA

Speakers:



Dr. Guilhem Roubaud
Institut Bergonié,
Bordeaux, France



Dr. Federico Cappuzzo
Regina Elena Institute,
Rome, Italy



Prof. Dr. Bence Sipos
BAG for Pathology and Molecular
Pathology, Stuttgart, Germany



Dr. Sara Pilotto
University Hospital,
Verona, Italy

Learning Objectives:

- To highlight the synergy between tissue and liquid biopsy testing in the diagnosis and treatment of solid tumours
- To explore the developing role of liquid biopsy in molecular testing and clinical practice
- To understand the practical implementation of liquid biopsy NGS in clinical routine

Agenda:

Time (CEST)	Session title	Speaker
10:15–10:25	The state of the art of liquid biopsy for solid tumour molecular testing	Dr. Christian Rolfo
10:25–10:40	Molecular testing in GU oncology: Addressing challenges and unmet needs	Dr. Guilhem Roubaud
10:40–10:55	Molecular testing in NSCLC: The role of liquid biopsy	Dr. Federico Cappuzzo
10:55–11:00	Q&A - oncologist perspective	All faculty
11:00–11:15	Practical insights on NGS implementation in clinical routine	Prof. Dr. Bence Sipos
11:15–11:40	Navigating real-world challenges: Case studies in oncology practice	Dr. Sara Pilotto
11:40–11:45	Conclusion	Dr. Christian Rolfo

We look forward to seeing you there

This industry symposium is funded and organised by Johnson & Johnson in collaboration with Thermo Fisher Scientific in EMEA and is intended for healthcare professionals only. Janssen Pharmaceutica NV, a Johnson & Johnson company, Turnhoutseweg 30, B-2340 Beerse, Belgium. Thermo Fisher Scientific - 3 Fountain Drive, Inchinnan Business Park, Paisley, PA4 9RF, UK.

GU, genitourinary; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

EM-159262 | August 2024

Process Maker Review: 54994-0624